{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:08:44Z","timestamp":1792681724043,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Immunotherapy with PD-1\/PD-L1 inhibitors has transformed advanced non-small cell lung cancer (NSCLC) treatment, yet optimal strategies for elderly patients remain uncertain. Elderly patients (\u2265\u200965\u00a0years) exhibit immune senescence (e.g., T-cell dysfunction, chronic inflammation), which may compromise immunotherapy efficacy and amplify toxicity risks, yet direct comparisons of monotherapy versus combination regimens in this population are lacking. Real-world comparisons of monotherapy versus combination therapy in this vulnerable group are lacking, hindering personalized clinical decisions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This real-world study aimed to compare the efficacy and safety of PD-1\/PD-L1 inhibitor monotherapy versus combination therapy with chemotherapy in elderly patients (\u2265\u200965\u00a0years) with advanced NSCLC and develop a prognostic nomogram to guide personalized treatment decisions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this multicenter retrospective study, 641 patients (149 monotherapy, 492 combination therapy) with stage IIIB\/IV NSCLC were analyzed. Primary endpoints included overall survival (OS), progression-free survival (PFS), and adverse events (AEs). A nomogram incorporating clinical variables was constructed using LASSO-Cox regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In a retrospective analysis of 641 elderly patients (\u2265\u200965\u00a0years) with advanced NSCLC, combination therapy (<jats:italic>n<\/jats:italic>\u2009=\u2009492) demonstrated superior median OS compared to monotherapy (<jats:italic>n<\/jats:italic>\u2009=\u2009149) (35.37 vs. 20.53\u00a0months; HR\u2009=\u20090.62, 95% CI 0.48\u20130.80, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), though PFS did not differ significantly (11.87 vs. 10.67\u00a0months; HR\u2009=\u20090.94, <jats:italic>P<\/jats:italic>\u2009=\u20090.535). Age-stratified analysis revealed marked OS benefits for patients\u2009&lt;\u200975\u00a0years receiving combination therapy (36.10 vs. 18.67\u00a0months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), whereas no advantage was observed in those\u2009\u2265\u200975\u00a0years (29.23 vs. 34.93\u00a0months, <jats:italic>P<\/jats:italic>\u2009=\u20090.645). Cox regression identified combination therapy as a protective factor (HR\u2009=\u20090.54, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), while ECOG PS\u2009\u2265\u20092 (HR\u2009=\u20091.87, <jats:italic>P<\/jats:italic>\u2009=\u20090.002), liver metastasis (HR\u2009=\u20091.62, <jats:italic>P<\/jats:italic>\u2009=\u20090.013), bone metastasis (HR\u2009=\u20091.84, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and malignant pleural effusion (HR\u2009=\u20091.64, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) independently worsened prognosis. The incidence of AEs of any-grade (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and grade 3\u20134 (<jats:italic>P<\/jats:italic>\u2009=\u20090.003) in the immunotherapy combination group was significantly higher than that in the immunotherapy monotherapy group. A prognostic nomogram integrating treatment type, ECOG PS score, and other six variables had an AUC value of 0.70\u20130.71 for predicting 1\u20132\u00a0year OS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>For elderly patients with advanced NSCLC, immune combination therapy improved median OS over monotherapy. It was safe and effective, suggesting a viable treatment option, though further evaluation is needed for those aged 75 and older. A prognostic nomogram for OS following immunotherapy was developed, showing superior accuracy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12890-025-03791-x","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T15:20:37Z","timestamp":1753284037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PD-1\/PD-L1 inhibitors monotherapy vs. combination therapy in elderly advanced NSCLC: a real-world study and nomogram for survival prognosis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9457-6664","authenticated-orcid":false,"given":"Yunye","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6032-1573","authenticated-orcid":false,"given":"An","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhao","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9319-5692","authenticated-orcid":false,"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-3487","authenticated-orcid":false,"given":"Jinliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"5","key":"3791_CR1","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022 [J]. CA Cancer J Clin. 2022;72(5):409\u201336.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3791_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3791_CR3","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.2147\/CMAR.S376510","volume":"14","author":"W Ge","year":"2022","unstructured":"Ge W, Wu N, Jalbert JJ, et al. Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy [J]. Cancer Manag Res. 2022;14:3191\u2013202.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"3791_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, et al. Combination strategies to maximize the benefits of cancer immunotherapy [J]. J Hematol Oncol. 2021;14(1):156.","journal-title":"J Hematol Oncol"},{"issue":"7689","key":"3791_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer [J]. Nature. 2018;553(7689):446\u201354.","journal-title":"Nature"},{"issue":"7","key":"3791_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater [J]. J Clin Oncol. 2019;37(7):537\u201346.","journal-title":"J Clin Oncol"},{"issue":"10183","key":"3791_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"11","key":"3791_CR8","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41(11):1992\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3791_CR9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999\u20132006.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3791_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial [J]. J Thorac Oncol. 2020;15(8):1351\u201360.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"3791_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial [J]. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"key":"3791_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","volume":"135","author":"K Nosaki","year":"2019","unstructured":"Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies [J]. Lung Cancer. 2019;135:188\u201395.","journal-title":"Lung Cancer"},{"issue":"10274","key":"3791_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, G\u00fcm\u00fc\u015f M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592\u2013604.","journal-title":"Lancet"},{"issue":"22","key":"3791_CR14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J]. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"12","key":"3791_CR15","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","volume":"16","author":"Y Yang","year":"2021","unstructured":"Yang Y, Sun J, Wang Z, et al. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study [J]. J Thorac Oncol. 2021;16(12):2109\u201320.","journal-title":"J Thorac Oncol"},{"key":"3791_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102394","volume":"106","author":"M Tagliamento","year":"2022","unstructured":"Tagliamento M, Frelaut M, Baldini C, et al. The use of immunotherapy in older patients with advanced non-small cell lung cancer. Cancer Treat Rev. 2022;106: 102394.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"3791_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","volume":"186","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn C, Blasco MA, Partridge L, et al. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243\u201378.","journal-title":"Cell"},{"issue":"20","key":"3791_CR18","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1158\/1078-0432.CCR-22-1687","volume":"28","author":"Y Taniguchi","year":"2022","unstructured":"Taniguchi Y, Shimokawa T, Takiguchi Y, et al. A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Na\u00efve Non-Small Cell Lung Cancer: TORG1630 [J]. Clin Cancer Res. 2022;28(20):4402\u20139.","journal-title":"Clin Cancer Res"},{"key":"3791_CR19","doi-asserted-by":"crossref","unstructured":"Liang H, Liu Z, Cai X, et al. PD-(L)1 inhibitors vs. chemotherapy vs. their combination in front-line treatment for NSCLC: An indirect comparison [J]. Int J Cancer. 2019;145(11):3011\u20133021.","DOI":"10.1002\/ijc.32366"},{"issue":"58","key":"3791_CR20","doi-asserted-by":"publisher","first-page":"33903","DOI":"10.1039\/C9RA04590B","volume":"9","author":"M Zhang","year":"2019","unstructured":"Zhang M, Liu K, Wang M. Development of cancer immunotherapy based on PD-1\/PD-L1 pathway blockade [J]. RSC Adv. 2019;9(58):33903\u201311.","journal-title":"RSC Adv"},{"issue":"1","key":"3791_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00432-025-06089-x","volume":"151","author":"S Endo","year":"2025","unstructured":"Endo S, Imai H, Mouri A, et al. Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged \u2265 75 years) with non-small cell lung cancer [J]. J Cancer Res Clin Oncol. 2025;151(1):43.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"3791_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034010","volume":"10","author":"L Li","year":"2020","unstructured":"Li L, Xu F, Chen Y, et al. Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review. BMJ Open. 2020;10(11): e034010.","journal-title":"BMJ Open"},{"issue":"5","key":"3791_CR23","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/1759-7714.13057","volume":"10","author":"CS Kuo","year":"2019","unstructured":"Kuo CS, Wang CC, Huang YC, et al. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer [J]. Thorac Cancer. 2019;10(5):1158\u201366.","journal-title":"Thorac Cancer"},{"key":"3791_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang Q, Chen Y, Li X, et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13: 964442.","journal-title":"Front Immunol"},{"key":"3791_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108111","volume":"236","author":"DR Principe","year":"2022","unstructured":"Principe DR, Kamath SD, Korc M, et al. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther. 2022;236: 108111.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"3791_CR26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.21037\/tlcr-23-144","volume":"13","author":"Y Bai","year":"2024","unstructured":"Bai Y, Yang W, K\u00e4smann L, et al. Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review [J]. Transl Lung Cancer Res. 2024;13(2):398\u2013422.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"3791_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40425-019-0600-6","volume":"7","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Lin Z, Zhang X, et al. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. J Immunother Cancer. 2019;7(1):120.","journal-title":"J Immunother Cancer"},{"issue":"21","key":"3791_CR28","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50. J Clin Oncol. 2021;39(21):2339\u201349.","journal-title":"J Clin Oncol"},{"issue":"14","key":"3791_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70036","volume":"13","author":"Y Ikezawa","year":"2024","unstructured":"Ikezawa Y, Morita R, Mizugaki H, et al. Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis [J]. Cancer Med. 2024;13(14): e70036.","journal-title":"Cancer Med"},{"key":"3791_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lungcan.2021.08.015","volume":"161","author":"K Morimoto","year":"2021","unstructured":"Morimoto K, Yamada T, Yokoi T, et al. Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer [J]. Lung Cancer. 2021;161:26\u201333.","journal-title":"Lung Cancer"},{"issue":"8","key":"3791_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00262-024-03734-1","volume":"73","author":"Y Chen","year":"2024","unstructured":"Chen Y, Han H, Cheng J, et al. Efficacy and safety of anti-PD-1\/PD-L1-based dual immunotherapies versus PD-1\/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis. Cancer Immunol Immunother. 2024;73(8):155.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3791_CR32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/jamaoncol.2023.6277","volume":"10","author":"Y Tsukita","year":"2024","unstructured":"Tsukita Y, Tozuka T, Kushiro K, et al. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2024;10(4):439\u201347.","journal-title":"JAMA Oncol"},{"issue":"6","key":"3791_CR33","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1111\/cas.15361","volume":"113","author":"Y Ikezawa","year":"2022","unstructured":"Ikezawa Y, Mizugaki H, Morita R, et al. Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression. Cancer Sci. 2022;113(6):2109\u201317.","journal-title":"Cancer Sci"},{"issue":"4","key":"3791_CR34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1189\/jlb.3RI0716-335R","volume":"102","author":"A Bektas","year":"2017","unstructured":"Bektas A, Schurman SH, Sen R, et al. Human T cell immunosenescence and inflammation in aging. J Leukoc Biol. 2017;102(4):977\u201388.","journal-title":"J Leukoc Biol"},{"key":"3791_CR35","doi-asserted-by":"publisher","first-page":"1476904","DOI":"10.3389\/fimmu.2024.1476904","volume":"15","author":"B Zhang","year":"2024","unstructured":"Zhang B, Liu J, Mo Y, et al. CD8(+) T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy. Front Immunol. 2024;15:1476904.","journal-title":"Front Immunol"},{"issue":"14","key":"3791_CR36","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhou Z, Dang Q, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12(14):6273\u201390.","journal-title":"Theranostics"},{"key":"3791_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.538174","volume":"11","author":"RC Nie","year":"2021","unstructured":"Nie RC, Chen GM, Wang Y, et al. Efficacy of Anti-PD-1\/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis. Front Oncol. 2021;11: 538174.","journal-title":"Front Oncol"},{"issue":"1","key":"3791_CR38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12889-025-21784-7","volume":"25","author":"MT Islam","year":"2025","unstructured":"Islam MT, Saif MSI, Alam N, et al. Evaluating the risk of comorbidity onset in elderly patients after a cancer diagnosis. BMC Public Health. 2025;25(1):640.","journal-title":"BMC Public Health"},{"issue":"11","key":"3791_CR39","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM, et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909\u201324.","journal-title":"J Thorac Oncol"},{"key":"3791_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.939249","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhou C, Zhang S, et al. Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Front Oncol. 2022;12: 939249.","journal-title":"Front Oncol"},{"issue":"9","key":"3791_CR41","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/1759-7714.13915","volume":"12","author":"T Isono","year":"2021","unstructured":"Isono T, Kagiyama N, Shibata S, et al. A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer. Thorac Cancer. 2021;12(9):1387\u201397.","journal-title":"Thorac Cancer"},{"issue":"1","key":"3791_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1186\/s12885-022-09674-2","volume":"22","author":"X Gu","year":"2022","unstructured":"Gu X, Shi Z, Shao L, et al. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study [J]. BMC Cancer. 2022;22(1):576.","journal-title":"BMC Cancer"},{"issue":"12","key":"3791_CR43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00262-024-03819-x","volume":"73","author":"Y Chen","year":"2024","unstructured":"Chen Y, Han H, Cheng J, et al. Correction to: Efficacy and safety of anti-PD-1\/PD-L1-based dual immunotherapies versus PD-1\/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis [J]. Cancer Immunol Immunother. 2024;73(12):263.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"3791_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1158\/1078-0432.CCR-21-3194","volume":"28","author":"H Hayashi","year":"2022","unstructured":"Hayashi H, Sugawara S, Fukuda Y, et al. A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clin Cancer Res. 2022;28(5):893\u2013902.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3791_CR45","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s10637-021-01069-7","volume":"39","author":"N Matsuo","year":"2021","unstructured":"Matsuo N, Azuma K, Kojima T, et al. Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy. Invest New Drugs. 2021;39(4):1150\u20138.","journal-title":"Invest New Drugs"},{"issue":"7","key":"3791_CR46","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.21037\/tlcr-21-575","volume":"10","author":"M Lin","year":"2021","unstructured":"Lin M, Vanneste BGL, Yu Q, et al. Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review. Transl Lung Cancer Res. 2021;10(7):3276\u201391.","journal-title":"Transl Lung Cancer Res"},{"issue":"9","key":"3791_CR47","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.21037\/jtd.2020.04.18","volume":"12","author":"I Amanam","year":"2020","unstructured":"Amanam I, Mambetsariev I, Gupta R, et al. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. J Thorac Dis. 2020;12(9):5086\u201395.","journal-title":"J Thorac Dis"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03791-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T22:59:07Z","timestamp":1757285947000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03791-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3791"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03791-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were followed by the ethical standards of the institutional research committee, along with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of the PLA General Hospital (No. 22023\u20138-26\u20131), with informed consent waived by the Institutional Review Board of the PLA General Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics committee approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"No disclosure of personal information in articles.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publicaton"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"350"}}